Corrigendum to “Reversing multidrug resistance by intracellular delivery of Pluronic® P85 unimers” [Biomaterials 34 (2013) 9602–9614, (Biomaterials (2013) 34(9602-9614) (S0142961213009800), (10.1016/j.biomaterials.2013.08.032));Reversing multidrug resistance by intracellular delivery of Pluronic® P85 unimers

Biomaterials

Volumn 34, Issue 37, 2013, Pages 9602-9614

  Hong, Wei ^a   Chen, Dawei ^a,b   Zhang, Xiaojun ^a   Zeng, Jianfu ^a   Hu, Haiyang ^a   Zhao, Xiuli ^a   Qiao, Mingxi ^a  

^a SHENYANG PHARMACEUTICAL UNIVERSITY   (China)

^b MEDICAL COLLEGE OF SOOCHOW UNIVERSITY   (China)

Author keywords

Intracellular delivery; Multidrug resistance; PH sensitive; Triggered release

Indexed keywords

CANCER CELLS; CELL MEMBRANES; CYTOLOGY; MICELLES; MITOCHONDRIA; PH SENSORS;

INTRACELLULAR DELIVERY; L-LACTIDE; MIXED MICELLES; MULTIDRUG RESISTANCE; PH SENSITIVE; PLURONICS; POLIES (LHISTIDINE); POLY-L-HISTIDINE; TRIGGERED RELEASE; UNIMERS;

AMINO ACIDS;

ADENOSINE TRIPHOSPHATE; COPOLYMER; DOXORUBICIN; DRUG CARRIER; FOLIC ACID; PLURONIC P 85; POLOXAMER; POLY(HISTIDINE) POLY(LACTIDE) POLYETHYLENEGLYCOL POLY(LACTIDE) POLY(HISTIDINE); UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER RESISTANCE; CELL ASSAY; CELL ENERGY; CELL PH; CELLULAR DISTRIBUTION; CONCENTRATION RESPONSE; CONFOCAL LASER MICROSCOPY; CONTROLLED STUDY; DRUG CONJUGATION; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; ENDOSOME; FEMALE; FILM; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IN VITRO STUDY; MICELLE; MITOCHONDRIAL MEMBRANE POTENTIAL; MITOCHONDRION; MOUSE; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; SURFACE TENSION;

INTRACELLULAR DELIVERY; MULTIDRUG RESISTANCE; PH SENSITIVE; PLURONIC(®) P85 UNIMERS; TRIGGERED RELEASE;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; BREAST; BREAST NEOPLASMS; CELL LINE, TUMOR; DELAYED-ACTION PREPARATIONS; DOXORUBICIN; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; FEMALE; HISTIDINE; HUMANS; MICE; MICE, INBRED BALB C; MICELLES; POLOXAMER; POLYESTERS; POLYETHYLENE GLYCOLS;

EID: 84884819138     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2022.121740     Document Type: Erratum

References (54)

1. Naito S., Yokomizo A., Koga H. Mechanisms of drug resistance in chemotherapy for urogenital carcinoma. Int J Urol 1999, 6:427-439.
2. Kroger N., Achterrath W., Hegewisch-Becker S., Mross K., Zander A.R. Current options in treatment of anthracycline-resistant breast cancer. Cancer Treat Rev 1999, 25:279-291.
3. Fields A., Hochster H., Runowicz C., Speyer J., Goldberg G., Cohen C., et al. PSC833: initial clinical results in refractory ovarian cancer patients. Curr Opin Oncol 1998, 10(Suppl.1):S21.
4. Wigler P.W. PSC833, cyclosporin A, and dexniguldipine effects on cellular calcein retention and inhibition of the multidrug resistance pump in human leukemic lymphoblasts. Biochem Biophys Res Commun 1999, 257:410-413.
5. Cruz F., Wolf A. Effects of the novel cyclosporine derivative PSC833 on glucose metabolism in rat primary cultures of neuronal and glial cells. Biochem Pharmacol 2001, 62:129-139.
6. Baekelandt M., Lehne G., Trope C.G., Szanto I., Pfeiffer P., Gustavssson B., et al. Phase I/II trial of the multidrug-resistance modulator valspodar combined with cisplatin and doxorubicin in refractory ovarian cancer. JClin Oncol 2001, 19:2983-2993.
7. Chico I., Kang M.H., Bergan R., Abraham J., Bakke S., Meadows B., et al. Phase I study of infusional paclitaxel in combination with the P-glycoprotein antagonist PSC 833. JClin Oncol 2001, 19:832-842.
8. Verschraegen C.F., Gupta E., Loyer E., Kavanagh J.J., Kudelka A.P., Freedman R.S., et al. Aphase II clinical and pharmacological study of oral 9-nitrocamptothecin in patients with refractory epithelial ovarian, tubal or peritoneal cancer. Anticancer Drugs 1999, 10:375-383.
9. Gottesman M.M., Fojo T., Bates S.E. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2002, 2:48-58.
10. Zgurskaya H.I., Nikaido H. Multidrug resistance mechanisms: drug efflux across two membranes. Mol Microbiol 2000, 37:219-225.
11. Venne A., Li S., Mandeville R., Kabanov A., Alakhov V. Hypersensitizing effect of pluronic L61 on cytotoxic activity, transport, and subcellular distribution of doxorubicin in multiple drug-resistant cells. Cancer Res 1996, 56:3626-3629.
12. Evers R., Kool M., Smith A.J., van Deemter L., de Haas M., Borst P. Inhibitory effect of the reversal agents V-104, GF120918 and Pluronic L61 on MDR1 Pgp-, MRP1- and MRP2-mediated transport. Br J Cancer 2000, 83:366-374.
13. Miller D.W., Batrakova E.V., Kabanov A.V. Inhibition of multidrug resistance-associated protein (MRP) functional activity with pluronic block copolymers. Pharm Res 1999, 16:396-401.
14. Yamagata T., Kusuhara H., Morishita M., Takayama K., Benameur H., Sugiyama Y. Effect of excipients on breast cancer resistance protein substrate uptake activity. JControl Release 2007, 124:1-5.
15. Yamagata T., Kusuhara H., Morishita M., Takayama K., Benameur H., Sugiyama Y. Improvement of the oral drug absorption of topotecan through the inhibition of intestinal xenobiotic efflux transporter, breast cancer resistance protein, by excipients. Drug Metab Dispos 2007, 35:1142-1148.
16. Dudeja P.K., Anderson K.M., Harris J.S., Buckingham L., Coon J.S. Reversal of multidrug resistance phenotype by surfactants: relationship to membrane lipid fluidity. Arch Biochem Biophys 1995, 319:309-315.
17. Kabanov A.V., Batrakova E.V., Alakhov V.Y. Pluronic block copolymers for overcoming drug resistance in cancer. Adv Drug Deliv Rev 2002, 54:759-779.
18. Van Aubel R.A., Koenderink J.B., Peters J.G., Van Os C.H., Russel F.G. Mechanisms and interaction of vinblastine and reduced glutathione transport in membrane vesicles by the rabbit multidrug resistance protein Mrp2 expressed in insect cells. Mol Pharmacol 1999, 56:714-719.
19. Bagrij T., Klokouzas A., Hladky S.B., Barrand M.A. Influences of glutathione on anionic substrate efflux in tumour cells expressing the multidrug resistance-associated protein, MRP1. Biochem Pharmacol 2001, 62:199-206.
20. Harbottle A., Daly A.K., Atherton K., Campbell F.C. Role of glutathione S-transferase P1, P-glycoprotein and multidrug resistance-associated protein 1 in acquired doxorubicin resistance. Int J Cancer 2001, 92:777-783.
21. Priebe W., Krawczyk M., Kuo M.T., Yamane Y., Savaraj N., Ishikawa T. Doxorubicin- and daunorubicin-glutathione conjugates, but not unconjugated drugs, competitively inhibit leukotriene C4 transport mediated by MRP/GS-X pump. Biochem Biophys Res Commun 1998, 247:859-863.
22. Evers R., de Haas M., Sparidans R., Beijnen J., Wielinga P.R., Lankelma J., et al. Vinblastine and sulfinpyrazone export by the multidrug resistance protein MRP2 is associated with glutathione export. Br J Cancer 2000, 83:375-383.
23. Alakhova D.Y., Rapoport N.Y., Batrakova E.V., Timoshin A.A., Li S., Nicholls D., et al. Differential metabolic responses to pluronic in MDR and non-MDR cells: a novel pathway for chemosensitization of drug resistant cancers. JControl Release 2010, 142:89-100.
24. Minko T., Batrakova E.V., Li S., Li Y., Pakunlu R.I., Alakhov V.Y., et al. Pluronic block copolymers alter apoptotic signal transduction of doxorubicin in drug-resistant cancer cells. JControl Release 2005, 105:269-278.
25. Altan N., Chen Y., Schindler M., Simon S.M. Defective acidification in human breast tumor cells and implications for chemotherapy. JExp Med 1998, 187:1583-1598.
26. van Veen H.W., Margolles A., Putman M., Sakamoto K., Konings W.N. Multidrug resistance in lactic acid bacteria: molecular mechanisms and clinical relevance. Antonie Van Leeuwenhoek 1999, 76:347-352.
27. Batrakova E., Lee S., Li S., Venne A., Alakhov V., Kabanov A. Fundamental relationships between the composition of pluronic block copolymers and their hypersensitization effect in MDR cancer cells. Pharm Res 1999, 16:1373-1379.
28. Batrakova E.V., Han H.Y., Miller D.W., Kabanov A.V. Effects of pluronic P85 unimers and micelles on drug permeability in polarized BBMEC and Caco-2 cells. Pharm Res 1998, 15:1525-1532.
29. Miller D.W., Batrakova E.V., Waltner T.O., Alakhov V., Kabanov A.V. Interactions ofpluronic block copolymers with brain microvessel endothelial cells: evidence of two potential pathways for drug absorption. Bioconjug Chem 1997, 8:649-657.
30. Batrakova E.V., Li S., Vinogradov S.V., Alakhov V.Y., Miller D.W., Kabanov A.V. Mechanism of pluronic effect on P-glycoprotein efflux system in blood-brain barrier: contributions of energy depletion and membrane fluidization. JPharmacol Exp Ther 2001, 299:483-493.
31. Batrakova E.V., Li S., Elmquist W.F., Miller D.W., Alakhov V.Y., Kabanov A.V. Mechanism of sensitization of MDR cancer cells by Pluronic block copolymers: selective energy depletion. Br J Cancer 2001, 85:1987-1997.
32. Zhang W., Shi Y., Chen Y., Ye J., Sha X., Fang X. Multifunctional Pluronic P123/F127 mixed polymeric micelles loaded with paclitaxel for the treatment of multidrug resistant tumors. Biomaterials 2011, 32:2894-2906.
33. Wang Y., Yu L., Han L., Sha X., Fang X. Difunctional Pluronic copolymer micelles for paclitaxel delivery: synergistic effect of folate-mediated targeting and Pluronic-mediated overcoming multidrug resistance in tumor cell lines. Int J Pharm 2007, 337:63-73.
34. Wang Y.L.Y., Zhang L., Fang X. Pharmacokinetics and biodistribution of paclitaxel-loaded pluronic P105 polymeric micelles. Arch Pharm Res 2008, 31:530-538.
35. Wang Y., Hao J., Li Y., Zhang Z., Sha X., Han L., et al. Poly(caprolactone)-modified Pluronic P105 micelles for reversal of paclitaxcel-resistance in SKOV-3 tumors. Biomaterials 2012, 33:4741-4751.
36. Mu C.F., Balakrishnan P., Cui F.D., Yin Y.M., Lee Y.B., Choi H.G., et al. The effects of mixed MPEG-PLA/Pluronic copolymer micelles on the bioavailability and multidrug resistance of docetaxel. Biomaterials 2010, 31:2371-2379.
37. Li X., Li P., Zhang Y., Zhou Y., Chen X., Huang Y., et al. Novel mixed polymeric micelles for enhancing delivery of anticancer drug and overcoming multidrug resistance in tumor cell lines simultaneously. Pharm Res 2010, 27:1498-1511.
38. Burt H.M., Zhang X., Toleikis P., Embree L., Hunter W.L. Development of copolymers of poly (D, L-lactide) and methoxy polyethylene glycol as micellar carriers of paclitaxel. Colloids Surf B Biointerfaces 1999, 16:161-171.
39. Zhang W., Shi Y., Chen Y., Yu S., Hao J., Luo J., et al. Enhanced antitumor efficacy by paclitaxel-loaded pluronic P123/F127 mixed micelles against non-small cell lung cancer based on passive tumor targeting and modulation of drug resistance. Eur J Pharm Biopharm 2010, 75:341-353.
40. Gaucher G., Dufresne M.H., Sant V.P., Kang N., Maysinger D., Leroux J.C. Block copolymer micelles: preparation, characterization and application in drug delivery. JControl Release 2005, 109:169-188.
41. Simon L., Szilagyi G., Bori Z., Telek G., Magyar K., Nagy Z. Low dose (-)deprenyl is cytoprotective: it maintains mitochondrial membrane potential and eliminates oxygen radicals. Life Sci 2005, 78:225-231.
42. Chen H., Ahn R., Van den Bossche J., Thompson D.H., O'Halloran T.V. Folate-mediated intracellular drug delivery increases the anticancer efficacy of nanoparticulate formulation of arsenic trioxide. Mol Cancer Ther 2009, 8:1955-1963.
43. Lo C.L., Huang C.K., Lin K.M., Hsiue G.H. Mixed micelles formed from graft and diblock copolymers for application in intracellular drug delivery. Biomaterials 2007, 28:1225-1235.
44. Liu D., Liu F., Song Y.K. Recognition and clearance of liposomes containing phosphatidylserine are mediated by serum opsonin. Biochim Biophys Acta 1995, 1235:140-146.
45. Yin H., Lee E.S., Kim D., Lee K.H., Oh K.T., Bae Y.H. Physicochemical characteristics of pH-sensitive poly(L-Histidine)-b-poly(ethylene glycol)/poly(L-Lactide)-b-poly(ethylene glycol) mixed micelles. JControl Release 2008 Mar 3, 126(2):130-138.
46. Zhang Y., Lam Y.M. Study of mixed micelles and interaction parameters for polymeric nonionic and normal surfactants. JNanosci Nanotechnol 2006, 6:3877-3881.
47. Belhoussine R., Morjani H., Millot J.M., Sharonov S., Manfait M. Confocal scanning microspectrofluorometry reveals specific anthracyline accumulation in cytoplasmic organelles of multidrug-resistant cancer cells. JHistochem Cytochem 1998, 46:1369-1376.
48. Belting M., Sandgren S., Wittrup A. Nuclear delivery of macromolecules: barriers and carriers. Adv Drug Deliv Rev 2005, 57:505-527.
49. Couvreur P. Drug vectorization or how to modulate tissular and cellular distribution of biologically active compounds. Ann Pharm Fr 2001, 59:232-238.
50. Oh K.T., Lee E.S., Kim D., Bae Y.H. L-histidine-based pH-sensitive anticancer drug carrier micelle: reconstitution and brief evaluation of its systemic toxicity. Int J Pharm 2008, 358:177-183.
51. Aouali N., El Btaouri H., Dumontet C., Eddabra L., Malagarie-Cazenave S., Madoulet C., et al. Accumulation of lactosylceramide and overexpression of a PSC833-resistant P-glycoprotein in multidrug-resistant human sarcoma cells. Oncol Rep 2011, 25:1161-1167.
52. Nagao K., Maeda M., Manucat N.B., Ueda K. Cyclosporine A and PSC833 inhibit ABCA1 function via direct binding. Biochim Biophys Acta 2013, 1831:398-406.
53. Garewal H.S., Ahmann F.R., Schifman R.B., Celniker A. ATP assay: ability to distinguish cytostatic from cytocidal anticancer drug effects. JNati Cancer Inst 1986, 77:1039-1045.
54. Allen C., Yu Y., Eisenberg A., Maysinger D. Cellular internalization of PCL(20)-b-PEO(44) block copolymer micelles. Biochim Biophys Acta 1999, 1421:32-38.